Home›Trial›NCT07144163
🔬NCT07144163Phase 3RECRUITING

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Study Summary

The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

Conditions
Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
Interventions / Drugs
AtumelnantPlacebo
View on ClinicalTrials.gov ↗
Sponsor
CRNX
Crinetics Pharmaceuticals
Endocrinology
D39/100
Study Details
Enrollment150 participants
Primary Completion—
Lead SponsorCrinetics Pharmaceuticals Inc.
Data Retrieved2026-04-11 04:10:51.260380+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.